1
|
Campanella A, Capasso A, Heltai S, Taccetti C, Albi E, Herishanu Y, Haggenburg S, Chatzikonstantinou T, Doubek M, Kättström M, Giannopoulos K, Simkovic M, Moreno C, Massaia M, Bumbea H, Alshemmari S, Ranghetti P, Perotta E, Martini F, Sant'Antonio E, Colia M, Combi C, Levi S, Kater AP, Hazenberg M, Nijhof IS, Hofsink Q, Demosthenous C, Kotaskova J, Zaleska J, Vrbacky F, Raya AM, Bisogno D, Tripoli IE, Popov VM, Roman V, Stavroyianni N, Karypidou M, Scarano E, Locatelli M, Frenquelli M, Scarfò L, Stamatopoulos K, Ghia P. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. Am J Hematol 2024; 99:745-750. [PMID: 38264829 DOI: 10.1002/ajh.27218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 12/21/2023] [Accepted: 01/01/2024] [Indexed: 01/25/2024]
Abstract
Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
Collapse
Affiliation(s)
- A Campanella
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - A Capasso
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - S Heltai
- IRCCS San Raffaele Hospital, Milan, Italy
| | - C Taccetti
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - E Albi
- IRCCS San Raffaele Hospital, Milan, Italy
| | - Y Herishanu
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Tel Aviv University, Tel-Aviv, Israel
| | | | | | - M Doubek
- University Hospital Brno, Brno, Czech Republic
| | - M Kättström
- Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
| | | | - M Simkovic
- 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
| | - C Moreno
- Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - M Massaia
- AO S.Croce e Carle, Cuneo, Italy
- Turin University, Turin, Italy
| | - H Bumbea
- University Emergency Hospital, Bucharest, Romania
- University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania
| | - S Alshemmari
- Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait
| | | | - E Perotta
- IRCCS San Raffaele Hospital, Milan, Italy
| | - F Martini
- IRCCS San Raffaele Hospital, Milan, Italy
| | | | - M Colia
- IRCCS San Raffaele Hospital, Milan, Italy
| | - C Combi
- IRCCS San Raffaele Hospital, Milan, Italy
| | - S Levi
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - A P Kater
- Amsterdam UMC, Amsterdam, The Netherlands
| | | | - I S Nijhof
- Amsterdam UMC, Amsterdam, The Netherlands
- St Antonius Hospital, Nieuwegein, The Netherlands
| | - Q Hofsink
- Amsterdam UMC, Amsterdam, The Netherlands
| | - C Demosthenous
- Centre for Research and Technology Hellas, Thessaloniki, Greece
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - J Kotaskova
- University Hospital Brno, Brno, Czech Republic
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - J Zaleska
- Medical University of Lublin, Lublin, Poland
| | - F Vrbacky
- 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
| | - A Mora Raya
- Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | | | - I E Tripoli
- AO S.Croce e Carle, Cuneo, Italy
- Turin University, Turin, Italy
| | - V M Popov
- Colentina Clinical Hospital, Bucharest, Romania
| | - V Roman
- Center of Immunology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania
| | - N Stavroyianni
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - M Karypidou
- Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - E Scarano
- IRCCS San Raffaele Hospital, Milan, Italy
| | - M Locatelli
- Laboratory Medicine Service, IRCCS San Raffaele Hospital, Milano, Italy
| | | | - L Scarfò
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - K Stamatopoulos
- Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - P Ghia
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| |
Collapse
|
2
|
Faggio G, Politano GG, Lisi N, Capasso A, Messina G. The structure of chemical vapor deposited graphene substrates for graphene-enhanced Raman spectroscopy. J Phys Condens Matter 2024; 36:195303. [PMID: 38286012 DOI: 10.1088/1361-648x/ad238a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/29/2024] [Indexed: 01/31/2024]
Abstract
Defects and nanocrystalline grain structures play a critical role in graphene-enhanced Raman spectroscopy (GERS). In this study, we selected three types of few-layer, polycrystalline graphene films produced by chemical vapor deposition (CVD), and we tested them as GERS substrates. The graphene structure was controlled by decreasing the CVD temperature, thus obtaining (i) polycrystalline with negligible defect density, (ii) polycrystalline with high defect density, (iii) nanocrystalline. We applied rhodamine 6G as a probe molecule to investigate the Raman enhancement. Our results show that nanocrystalline graphene is the most sensitive GERS substrate, indicating that the GERS effect is primarily connected to the nanocrystalline structure, rather than to the presence of defects.
Collapse
Affiliation(s)
- G Faggio
- Department of Information Engineering, Infrastructures and Sustainable Energy (DIIES), University 'Mediterranea' of Reggio Calabria, Loc. Feo di Vito, 89122 Reggio, Calabria, Italy
| | - G G Politano
- Department of Information Engineering, Infrastructures and Sustainable Energy (DIIES), University 'Mediterranea' of Reggio Calabria, Loc. Feo di Vito, 89122 Reggio, Calabria, Italy
| | - N Lisi
- Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile (ENEA), Casaccia Research Centre, Roma 00123, Italy
| | - A Capasso
- International Iberian Nanotechnology Laboratory (INL), Braga 4715-330, Portugal
| | - G Messina
- Department of Information Engineering, Infrastructures and Sustainable Energy (DIIES), University 'Mediterranea' of Reggio Calabria, Loc. Feo di Vito, 89122 Reggio, Calabria, Italy
| |
Collapse
|
3
|
Khalezova N, Capasso A, Boeva E, Gutova L, Rassokhin V, Neznanov N, Belyakov N, Brown J, DiClemente R. Situational and motivational factors associated with unhealthy alcohol use among Russian women with HIV and hepatitis C Virus co-infection. Drug and Alcohol Dependence Reports 2022; 3. [PMID: 35783993 PMCID: PMC9246056 DOI: 10.1016/j.dadr.2022.100053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/29/2022]
|
4
|
Bendell J, Ulahannan S, Koczywas M, Brahmer J, Capasso A, Eckhardt S, Gordon M, McCoach C, Nagasaka M, Ng K, Pacheco J, Riess J, Spira A, Steuer C, Dua R, Chittivelu S, Masciari S, Wang Z, Wang X, Ou S. Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31089-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Marín Jiménez J, Capasso A, Bagby S, Hartman S, Shulman J, Barkow J, Yacob B, Blatchford P, Pitts T, Lang J. Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 2019; 7:37. [PMID: 30736857 PMCID: PMC6368764 DOI: 10.1186/s40425-019-0518-z] [Citation(s) in RCA: 107] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 01/21/2019] [Indexed: 12/13/2022] Open
Abstract
Background The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies, methods to test the potential anti-tumor activity of rational combination therapies are still needed. Conventional murine xenograft models have been hampered by their immune-compromised status; thus, we developed a hematopoietic humanized mouse model, hu-CB-BRGS, and used it to study anti-tumor human immune responses to triple-negative breast cancer (TNBC) cell line and patient-derived colorectal cancer (CRC) xenografts (PDX). Methods BALB/c-Rag2nullIl2rγnullSIRPαNOD (BRGS) pups were humanized through transplantation of cord blood (CB)-derived CD34+ cells. Mice were evaluated for human chimerism in the blood and assigned into experimental untreated or nivolumab groups based on chimerism. TNBC cell lines or tumor tissue from established CRC PDX models were implanted into both flanks of humanized mice and treatments ensued once tumors reached a volume of ~150mm3. Tumors were measured twice weekly. At end of study, immune organs and tumors were collected for immunological assessment. Results Humanized PDX models were successfully established with a high frequency of tumor engraftment. Humanized mice treated with anti-PD-1 exhibited increased anti-tumor human T-cell responses coupled with decreased Treg and myeloid populations that correlated with tumor growth inhibition. Combination therapies with anti-PD-1 treatment in TNBC-bearing mice reduced tumor growth in multi-drug cohorts. Finally, as observed in human colorectal patients, anti-PD-1 therapy had a strong response to a microsatellite-high CRC PDX that correlated with a higher number of human CD8+ IFNγ+ T cells in the tumor. Conclusion Hu-CB-BRGS mice represent an in vivo model to study immune checkpoint blockade to human tumors. The human immune system in the mice is inherently suppressed, similar to a tumor microenvironment, and thus allows growth of human tumors. However, the suppression can be released by anti-PD-1 therapies and inhibit tumor growth of some tumors. The model offers ample access to lymph and tumor cells for in-depth immunological analysis. The tumor growth inhibition correlates with increased CD8 IFNγ+ tumor infiltrating T cells. These hu-CB-BRGS mice provide a relevant preclinical animal model to facilitate prioritization of hypothesis-driven combination immunotherapies. Electronic supplementary material The online version of this article (10.1186/s40425-019-0518-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A Capasso
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - J Lang
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA.
| | - T M Pitts
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - K R Jordan
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - C H Lieu
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - S L Davis
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - J R Diamond
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - S Kopetz
- MD Anderson Cancer Center, 1515 Holcombe Blvd10, Houston, TX, 77030, USA
| | - J Barbee
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - J Peterson
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - B M Freed
- Division of Allergy and Clinical Immunology, School of Medicine, University of Colorado Denver, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - B W Yacob
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - S M Bagby
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - W A Messersmith
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - J E Slansky
- University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA.,Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - R Pelanda
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - S G Eckhardt
- Department of Oncology, Dell Medical School, The University of Texas at Austin, 1701 Trinity Street, Austin, TX, 78712, USA
| |
Collapse
|
7
|
Tentler JJ, Frank JG, Kim DJ, George C, Lee YB, Ely B, Tan AC, Kim J, Pitts TM, Capasso A, Dailey KL, Eckhardt G, Diamond JR. Abstract P5-21-16: Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: RX-5902 (Supinoxin) is a novel anti-cancer compound that targets phosphorylated p68 RNA helicase, a member of the DEAD box family of helicases, affecting upstream and downstream molecules in the Wnt canonical pathway. As a single agent, RX-5902 exhibits strong growth inhibition in both in vitro and in vivo settings. Specifically, RX-5902 enhances survival and tumor growth inhibition in numerous xenograft models, including ovarian, renal and breast. We have previously shown RX-5902 inhibits cell growth in a dose-dependent fashion in the triple-negative breast cancer (TNBC) xenograft MDA-MB231. In the current study, we have expanded our investigation of the therapeutic potential of RX-5902 against TNBC using both in vitro and in vivo preclinical models.
Methods: RX-5902 was provided by Rexahn, Inc. (Rockville, MD). Cell proliferation was measured using the Cell-Titer Glo luminescent cell viability assay (Promega). Apoptosis was assessed using Incucyte Caspase 3/7 Green apoptosis assay (Essenbioscience). Immunoblots of MDA-MB-231 cell line were probed for ß-catenin (Cell Signaling). Syngeneic 4T1 murine TNBC mice were obtained from Sippr-BK Laboratory Animal Co (Shanghai, China) and tumor volumes were measured twice a week. When the mean tumor volumes reached ˜90 mm3, mice were randomized and treated with vehicle or RX-5902 PO daily alone or in combination with anti-CTLA4 or anti-PD-1 BIW for 3 weeks. Tumor growth inhibition (TGI) was calculated at Day 25.
Results: A panel of 18 TNBC cell lines were treated with RX-5902 and effects on cell proliferation were measured by the Cell Titer-Glo assay. Using 100nM as a cutoff, 14 sensitive lines and 4 resistant lines were identified, with an average IC50 of 56 nM in the sensitive lines. Of these, we chose 2 sensitive lines (MDA-MB-231, HCC1806) and 2 resistant lines (MDA-MB-436 and CAL-120) and assessed induction of apoptosis by the Incucyte caspase activity assay. Robust induction of apoptosis was observed in both sensitive lines (N=3). These lines were then subjected to cell cycle analysis by flow cytometry, which revealed a pronounced G2/M cell cycle arrest and aneuploidy following exposure to RX-5902. Western blot analysis of the MDA-MB-231 cell line showed decreases in the Wnt pathway-related protein nuclear ß-catenin in doses ranging from 20 nM to 200 nM. Finally, the therapeutic efficacy of RX-5902 was assessed as a single agent and in combination with two immune-oncology agents in the treatment of the TNBC 4T1 animal model. RX-5902 as a single agent showed dose dependency in the 4T1 model, and when given in combination with either anti-CTLA4 or anti-PD1 showed an additive effect (p<0.001). All the treatments were well-tolerated and no severe body weight loss was observed in this study.
Conclusions: RX-5902 showed efficacy against several in vitro and in vivo preclinical models of TNBC. RX-5902 resulted in G2/M arrest and induced apoptosis in sensitive TNBC cell lines and decreases in nuclear beta-catenin. In vivo, RX-5902 demonstrated additive anti-tumor effects when combined with either anti-CTLA4 or anti-PD1 immunotherapies. Together, these finding indicate that RX-5902 may have important clinical implications for the treatment of TNBC. A phase 2a clinical study in metastatic TNBC is ongoing..training_cert
Citation Format: Tentler JJ, Frank JG, Kim DJ, George C, Lee YB, Ely B, Tan AC, Kim J, Pitts TM, Capasso A, Dailey KL, Eckhardt G, Diamond JR. Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-16.
Collapse
Affiliation(s)
- JJ Tentler
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - JG Frank
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - DJ Kim
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - C George
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - YB Lee
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - B Ely
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - AC Tan
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - J Kim
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - TM Pitts
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - A Capasso
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - KL Dailey
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - G Eckhardt
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - JR Diamond
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| |
Collapse
|
8
|
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Abstract PD3-16: Clinical safety and efficacy of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd3-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the lack of expression of the estrogen and progesterone receptors and lack of HER2 over-expression. ENMD-2076 is an orally bioavailable small molecule inhibitor of Aurora and angiogenic kinases with pro-apoptotic and antiproliferative activity in preclinical models of TNBC.
Methods: This two institution, single-arm, two-stage, phase II clinical trial enrolled patients with locally advanced or metastatic TNBC refractory to 1-3 prior lines of chemotherapy in the advanced setting. Patients had ECOG PS ≤ 1, measureable disease by RECIST 1.1 and no evidence of brain metastasis. Patients were treated with ENMD-2076 250 mg PO daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity occurred. The primary end point was 6-month clinical benefit rate (6-CBR) and secondary endpoints included time to progression (TTP), PK profile, safety and biologic correlatives in archival and fresh serial tumor biopsies in a subset of patients.
Results: Between July 2012 and October 2016, 41 patients were enrolled (median age 54; range 30-73; female 40; male 1). Patients received a mean 1.7 prior lines of chemotherapy for locally advanced unresectable or metastatic disease and 80.5% received prior neoadjuvant or adjuvant chemotherapy (N=33). Thirty-six patients were evaluable per protocol for the primary efficacy analysis. Five patients (12.2%) were not included in the efficacy analysis due to: adverse events (AE) leading to discontinuation prior to objective efficacy assessment (N=3), not meeting eligibility criteria on day 1 (N=1) and withdraw of consent in cycle 1 (N=1). The study proceeded to the second stage of enrollment based on observing three 6-CBR events in Stage 1 (N=18 patients). The 6-CBR in the overall trial was 16.7% (95% exact CI: 6%-32.8%; 2 patients with PR and 4 patients with SD > 6 mos). The median duration of response or clinical benefit in these patients was 32 weeks (8 cycles). 4-CBR was 27.8% (95% exact CI: 14%-45.2%). Dose reduction occurred in 8 patients (20%) for fatigue, hypertension and proteinuria. The most common grade 3 treatment-related adverse events were hypertension (37.5%) and fatigue (10%). One patient experienced grade 4 hypertension. Analysis of serial tumor biopsies prior to and following 2 weeks of ENMD-2076 (N=8 patients), demonstrated a treatment-induced decrease in cellular proliferation (Ki-67) and microvessel density (CD34) as assessed by IHC. Immunofluorescence performed on a subset of samples demonstrated an increase in p53-family member expression following treatment, consistent with changes observed in preclinical TNBC patient-derived tumor xenograft models.
Conclusions: ENMD-2076 has durable clinical activity in a subset of patients with pretreated, advanced or metastatic triple-negative breast cancer. Predictive biomarker development using archival and fresh tumor tissue is underway. Exploration of lower doses of ENMD-2076 in future clinical trials may improve tolerability.
Citation Format: Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Clinical safety and efficacy of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-16.
Collapse
Affiliation(s)
- JR Diamond
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - SG Eckhardt
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - TM Pitts
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - A van Bokhoven
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - D Aisner
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - DL Gustafson
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - A Capasso
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - AD Elias
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - AM Storniolo
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - BP Schneider
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - D Gao
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - JJ Tentler
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - VF Borges
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - KD Miller
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| |
Collapse
|
9
|
Ventriglia J, laterza M, Capasso A, Belli V, Savastano B, Petrillo A, Tirino G, Pompella L, Diana A, Orditura M, Ciardiello F, De Vita F. GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Savastano B, laterza M, Capasso A, Belli V, Ventriglia J, Petrillo A, Tirino G, Pompella L, Morgillo F, Martinelli E, Orditura M, Ciardiello F, De Vita F. The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Cardone C, Sforza V, Nappi A, Capasso A, Ferrara M, Martini G, Napolitano S, Vitiello P, Vitale P, Zanaletti N, Diadema M, Orditura M, De Vita F, Troiani T, Ciardiello F, Martinelli E. Outcomes of elderly chemorefractory metastatic colorectal (mCRC) patients (pts) treated with regorafenib: a single institution experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Sforza V, Capasso A, Nappi A, Cardone C, Martini G, Ferrara M, Napolitano S, Vitiello P, Vitale P, Zanaletti N, De Vita F, Orditura M, Troiani T, Ciardiello F, Martinelli E. Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Troiani T, Sforza V, Cardone C, Nappi A, Capasso A, Martini G, Napolitano S, Zanaletti N, Vitale P, Vitiello P, De Vita F, Orditura M, Ferrara M, Ciardiello F, Martinelli E. Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts): a single institution experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Troiani T, Napolitano S, Martinelli E, Vitagliano D, Martini G, Morgillo F, Cardone C, Capasso A, Gambardella V, Venturini F, Ciardiello F. Optimal Strategy with Multi-Targeted Therapies in Egfr-Dependent “Quadruple Wild Type (Wt) for Kras, Braf, Nras and Pik3Ca Genes” Colorectal Cancer (Crc) Xenografts After Combined Treatment of Irinotecan Plus Cetuximab. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Capasso A, Gambardella V, Martinelli E, Troiani T, Nappi A, Sforza V, Manzo A, Martini G, Della Corte C, Napolitano S, Laterza M, Morgillo F, Vitagliano D, Orditura M, De Vita F, Ciardiello F. Cell Growth Inhibition of Her2 Positive Trastuzumab Resistant Gastric Cancer Cell Lines By Combined Inhibition of Pi3K/Akt/Mtor and Mapk. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Martini G, Troiani T, Vitagliano D, Napolitano S, Morgillo F, Liotti F, Melillo R, Vitiello P, Capasso A, Gambardella V, Ciardiello D, Venturini F, Cardone C, Orditura M, Ciardiello F, Martinelli E. Axl Tyrosine Kinase Receptor As a Key Regulator of Proliferation and Survival in Colorectal Cancer (Crc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Milano W, De Rosa M, Milano L, Riccio A, Sanseverino B, Capasso A. The pharmacological options in the treatment of eating disorders. ISRN Pharmacol 2013; 2013:352865. [PMID: 23956871 PMCID: PMC3727200 DOI: 10.1155/2013/352865] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Accepted: 06/18/2013] [Indexed: 11/18/2022]
Abstract
The eating disorders (DCA) are complex systemic diseases with high social impact, which tend to become chronic with significant medical and psychiatric comorbidities. The literature data showed that there is good evidence to suggest the use of SSRIs, particularly at high doses of fluoxetine, in the treatment of BN reducing both the crisis of binge that the phenomena compensates and reducing the episodes of binge in patients with BED in the short term. Also, the topiramate (an AED) showed a good effectiveness in reducing the frequency and magnitude of episodes of binge with body weight reduction, both in the BN that is in the therapy of BED. To date, modest data support the use of low doses of second-generation antipsychotics in an attempt to reduce the creation of polarized weight and body shapes, the obsessive component, and anxiety in patients with AN. Data in the literature on long-term drug treatment of eating disorders are still very modest. It is essential to remember that the pharmacotherapy has, however, a remarkable efficacy in treating psychiatric disorders that occur in comorbidity with eating disorders, such as mood disorders, anxiety, insomnia, and obsessive-compulsive personality disorders and behavior.
Collapse
Affiliation(s)
- W. Milano
- Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
| | - M. De Rosa
- Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
| | - L. Milano
- Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
| | - A. Riccio
- Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
| | - B. Sanseverino
- Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
| | - A. Capasso
- Department of Pharmacy, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy
| |
Collapse
|
18
|
Milano W, De Rosa M, Milano L, Riccio A, Sanseverino B, Capasso A. Successful Treatment with Agomelatine in NES: A Series of Five Cases. Open Neurol J 2013; 7:32-7. [PMID: 24133551 PMCID: PMC3795402 DOI: 10.2174/1874205x20130626001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2013] [Accepted: 06/20/2013] [Indexed: 11/22/2022] Open
Abstract
The NES is an emerging disease in eating behavior that combines eating disorders, sleep, mood and stress. In recent years, the NES is becoming more interested in close association with obesity and depression. In the present study we have followed for 12 weeks 5 patients (2 males and 3 females) with NES and comorbid depression treated with agomelatine (25 mg / day for the first two weeks, then 50 mg / day), an antidepressant similar of melatonin. At the end of the three months of treatment, it was found an improvement in symptoms characteristic of the NES, as assessed by a reduction an average of the NEQ (from 31 to 22.8), improved mood, mean values reduced by 23, 2 to 13.2 on the HAM-D, weight reduction, an average of 3.6 kg reduction in average weekly awakenings from 12 to 6.4 and the time of snoring and motion detected polysomnography. The serum chemistry values remained stable and there were no reported adverse events. The present study showed that the treatment with agomelatine has improved the symptoms of NES and mood, decrease of body weight, reduce, albeit not in an optimal manner, the number of awakenings per night with a reduction of movement time and snoring . Of course, these preliminary data need to be confirmed by controlled trials on a larger sample.
Collapse
Affiliation(s)
- W Milano
- Mental Health Unit- Distrect 24 - ASL Napoli 1 Center Department of Pharmacy, University of Salerno, Italy
| | | | | | | | | | | |
Collapse
|
19
|
Amarelli C, Montibello M, Casale D, Verniero L, Capasso A, Galdieri N, Santè P, Maiello C. OP-189 ECMO WITH BIVALURIDIN IN EXTUBATED PATIENT: THE “HOLY GRAIL” OF ECMO OR ONLY A FASHIONABLE POLICY? Int J Cardiol 2013. [DOI: 10.1016/s0167-5273(13)70190-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Festa M, Caputo M, Cipolla C, D'Acunto CW, Rossi AG, Tecce MF, Capasso A. The involvement of xanthohumol in the expression of annexin in human malignant glioblastoma cells. Open Biochem J 2013; 7:1-10. [PMID: 23407460 PMCID: PMC3568876 DOI: 10.2174/1874091x01307010001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Revised: 10/12/2012] [Accepted: 10/23/2012] [Indexed: 11/22/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most common malignant and resistant tumor of the central nervous system in humans and new therapeutic strategies are urgently required. Recently, we have shown that the potential chemotherapeutic polyphenol xanthohumol (XH), isolated from Humulus Lupulus, induces apoptosis of human T98G glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways. Then we have found, by western blotting and microscopic analysis, that XH up-regulates cytosolic levels of ANXA1 and induces translocation of the protein on the cell membrane of T98G cells in a time-dependent manner with significant effects observed after 24 h. On the basis of the above evidence, the aim of this work was to investigate the role of intracellular and cell membrane localized ANXA1 in GBM cells. RT-PCR analysis has shown that XH up-regulates mRNA levels of ANXA1 after 16 h treatment. To demonstrate the involvement of ANXA1 in apoptosis of GBM cells we down-regulated ANXA1 expression with small interfering RNA (siRNA) and then analysed apoptosis in the presence and absence of apoptotic stimuli. Importantly, apoptosis induced by XH was reduced in siRNA-ANXA1 transfected cells where western blot analysis shows a significant reduction of ANXA1 protein levels. To investigate the role of ANXA1 expression on the cell membrane of T98G cells as potential "eat-me" signal we studied phagocytosis of apoptotic cells by human macrophages. We incubated apoptotic T98G cells with human blood monocyte derived macrophages (M=). After co-incubation period we analysed the percentage of M= phagocytosing the apoptotic cells by cytofluorimetric FACS analysis and by confocal microscopy. Our results show that XH induces phagocytosis of apoptotic T98G cells by human M= in a concentration-effect manner, a processes that is dependent on caspase mediated apoptosis. ANXA1 acts as an "eat-me" signal on the cell membrane of T98G cells, and interestingly, apoptotic siRNA-ANXA1 transfected cells are not completely ingested by M=. These results were confirmed by incubating apoptotic cells with a neutralizing anti-ANXA1 antiboby and ANXA1 membrane depletion by EDTA washing. ANXA1 was also detected in supernatants of apoptotic cells and the incubation of enriched supernatants enhanced the percentage of phagocytosis by M=. These results demonstrated that ANXA1 is involved both in the apoptosis and phagocytosis of glioblastoma cells. This study shows a possible role of ANXA1 in maintenance of brain homeostasis and may lead to novel therapeutic approaches for neuro-inflammatory diseases and chemotherapy targets in the treatment of glioblastoma multiforme.
Collapse
Affiliation(s)
- M Festa
- University of Salerno, Department of Pharmacy, Italy
| | - M Caputo
- University of Salerno, Department of Pharmacy, Italy
| | - C Cipolla
- University of Salerno, Department of Pharmacy, Italy
| | - CW D'Acunto
- University of Salerno, Department of Pharmacy, Italy
| | - AG Rossi
- University of Edinburgh, MRC Centre for Inflammation Research, UK
| | - MF Tecce
- University of Salerno, Department of Pharmacy, Italy
| | - A Capasso
- University of Salerno, Department of Pharmacy, Italy
| |
Collapse
|
21
|
Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F, Ciardiello F. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets 2012; 13:802-10. [PMID: 22458527 DOI: 10.2174/138945012800564158] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2010] [Revised: 02/04/2012] [Accepted: 03/27/2012] [Indexed: 12/14/2022]
Abstract
The prognosis of patients with pancreatic cancer is extremely poor, and current systemic therapies provide marginal survival benefits for treated patients. The era of targeted therapies has offered a new avenue to search for potentially more effective strategies. Epidermal growth factor receptor (EGFR) is a member of the erbB/human epidermal growth factor receptor family of tyrosine kinases, which includes erbB2/HER2, erbB3/HER3 and erbB4/HER4. Epidermal growth factor receptor overexpression may be detected in up to 90% of pancreatic tumors. Two pharmacologic approaches have been successfully used to inhibit epidermal growth factor receptor function in cancer treatment: neutralizing monoclonal antibodies and small molecule tyrosine inhibitors. The randomized trials studying the addition of EGFR targeted agents to gemcitabine compared with gemcitabine alone have been disappointing, although results with the EGFR tyrosine kinase inhibitor erlotinib were statistically significant but clinically of marginal benefit. In this article, we review the epidermal growth factor receptor signaling network in pancreatic cancer, the strategies to increase the effectiveness of epidermal growth factor receptor inhibitors, and the clinical trials of these inhibitors in pancreatic cancer.
Collapse
Affiliation(s)
- T Troiani
- Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassie A. Zanzara, Seconda Università degli Studi di Napoli, Naples, Italy
| | | | | | | | | | | | | |
Collapse
|
22
|
Troiani T, Vitagliano D, Napolitano S, Morgillo F, Capasso A, Sforza V, Nappi A, Berrino L, Ciardiello F, Martinelli E. Met Activation by Autocrine Loop Rescues Colon Cancer Cells From Sensitivity to EGFR Inhibition. Ann Oncol 2012. [DOI: 10.1093/annonc/mds390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Loizzo S, Capasso A, Loizzo AL, Spampinato S, Campana G, Di Giannuario A, Pieretti S, Loizzo A. Pain and child: a translational hypothesis on the pathophysiology of a mild type-2 diabetes model. Endocr Metab Immune Disord Drug Targets 2011; 11:1-7. [PMID: 21348823 DOI: 10.2174/187153011794982040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Accepted: 12/07/2010] [Indexed: 11/22/2022]
Abstract
Pediatric pain management underwent many changes since the undertreatment of pain in children was reported in the literature in 1980. Increasing data also suggest that long-term behavioural effects can be observed in children, following pain episodes as early as in the neonatal period. Therefore, the knowledge about safe and effective management of pain in children should be applied with greater effectiveness into clinical practice. Other advances in the field include the findings of long-term residual behavioural and metabolic effects induced by pain experienced during the critical periods of development in laboratory animals. Recent data in laboratory animals and clinical data in children suggest that early repeated and/or severe pain and other stressful procedures applied in the perinatal periods may produce not only behavioral, but also important hormonal, immune and metabolic long-term effects. In this paper we shall report data on some metabolic conditions described in adult humans following disruption of hormonal-metabolic programming produced in the peri-natal period. Quite similar signs can be found between animal models and human conditions, most of them being connected with hypothalamus-pituitary-adrenal hormones (HPA) dysfunction. In addition, some signs in animal models, such as overweight and abdominal overweight are prevented by treatment with the μ- and δ-opioid receptor antagonist naloxone during the lactating period. This indicates that some long-term consequences following stress received during the early phases of life in mammals may be bound to the HPA system dysregulation, whereas others are bound to different (e,g., opioid) endogenous brain receptors and/or neuromediators alteration.
Collapse
Affiliation(s)
- S Loizzo
- Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011; 11:31-4. [PMID: 21250937 DOI: 10.2174/187152411794961086] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2010] [Accepted: 12/27/2010] [Indexed: 11/22/2022]
Abstract
In the last years, the hypothesis that cortical hyperexcitability may play a role in the physiopathology of migraine led to the therapeutic use of some antiepileptic drugs. To evaluate the efficacy of levetiracetam as prophylactic treatment for migraine without aura in elderly patients. We performed a small open-label trial treating 13 elderly patients(8F 5M) mean age 64.7 years (SD 3.4), range 60-72 years affected by migraine without aura (ICDH '04 criteria). The mean age of disease was 21.3 years (SD13.4) range 2-45 years. At baseline: the frequency of attacks was 12.2/month (SD 5.9), range 6-25; the mean number of drugs for acute attacks was 12.6 (SD 6.5) tablets/month. All patients took concomitant medication for other chronic diseases. After recruitment Levetiracetam 500 mg/die was administered for 1 week and 1000 mg/die for six months. The basal frequency of attack was 12,2 (SD 5.9) and 8,3 (SD 4.9), 4,1 (SD2.6), 1,3 (SD1.4) after 1, 3 and 6 months respectively [P=0.079; P<0.0001; P<0.0001].The basal value of intaking drugs for acute attacks was 12,6 (SD 6.5) and 6,7 (SD 4.3), 2,8 (SD 2.2), 1,4 (SD1.7) after 1, 3 and six months respectively [P=0.012; P<0.0001; P<0.0001](T-test analysis). Levetiracetam was well tolerated (7 patients complained somnolence, lack of concentration and gastralgia but none patient withdrew the study). In our study levetiracetam showed a good efficacy in frequency and intensity reduction of headache attack and showed a very good tolerability despite all elderly patients took drugs for concomitant diseases.
Collapse
Affiliation(s)
- V Pizza
- Neurophysiopatology Unit, S. Luca Hospital, Vallo della Lucania (SA), Italy
| | | | | | | | | |
Collapse
|
25
|
Peduto A, More V, de Caprariis P, Festa M, Capasso A, Piacente S, De Martino L, De Feo V, Filosa R. Synthesis and Cytotoxic Activity of New β-Carboline Derivatives. Mini Rev Med Chem 2011; 11:486-91. [DOI: 10.2174/138955711795843383] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2010] [Accepted: 03/29/2011] [Indexed: 11/22/2022]
|
26
|
Grimaldi C, Capasso A. The Endocannabinoid System in the Cancer Therapy: An Overview. Curr Med Chem 2011; 18:1575-83. [DOI: 10.2174/092986711795471374] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Accepted: 03/14/2011] [Indexed: 11/22/2022]
|
27
|
Pizza V, Bisogno A, Lamaida E, Agresta A, Bandieramonte G, Volpe A, Galasso R, Galasso L, Caputo M, Tecce MF, Capasso A. Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. Cent Nerv Syst Agents Med Chem 2010; 10:91-6. [PMID: 20518725 DOI: 10.2174/187152410791196404] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Genetic factors that increase susceptibility to oxidative stress, endothelial disfunction and, possibly, stroke include angiotensin-converting enzyme gene deletion polymorphism (ACE-DD) and the methylentetrahydropholate reductase (MTHFR) C677-TT polymorphism. The relationship of ACE-DD genotype to ischemic stroke and cardiovascular disease is controversial, but it has been independently linked to lacunar infarction, in the absence of carotid atheroma. Lea et al. (2005) reported that the ACE DD genotype acts in combination with the MTHFR T/T genotype to increase migraine susceptibility, with the greatest effect in those with aura. The "TT" polymorphism is also associated with an increased risk of migraine with aura, independent of other cardiovascular risk factors. The aim of our study was to evaluate the incidence of ACE and MTHFR genes polymorphisms in a consecutive series of migrainous patients and of patients affected by myocardial infarction. We studied a series of 103 migrainous patients (1), whose age was between 13 and 75 years (81 suffering from migraine without aura, MwA, 9 from migraine with aura, MWA, 13 from mixed forms MwA-MWA, according to ICHD-II 2004 criteria) and of 336 patients (2) suffering from ischaemic cardiopathy (myocardial infarction, MI). The analysis, based on Polymerase Chain Reaction (PCR) and on reverse-hybridization, showed as follows: MTHFR (C677T): 60 patients (58%) (1) and 186 (56%) (2) were heterozygous; 9 patients (9%) (1) and 54 (16%) (2) were mutated. The result of 1 patient (2) was unknown. MTHFR (A1298C): 54 patients (52%) (1) and 146 (44%) (2) were heterozygous, 7 patients (7%) (1) and 33 (10%) (2) were mutated. The result of 1 patient (2) was unknown. ACE (evaluated on 101 patients (1) and 245 (2)): 45 patients (43%) (1) and 133 (54%) (2) had an ID genotype; 42 (41%) (1) and 87 (36%) (2) had a DD genotype. The results of our study confirm the high incidence in the genetic polymorphisms ACE and MTHFR in migraineuse. These data are confirmed in the sample of patients affected by myocardial infarction. This gives evidence of a strong relationship between migraine and major vascular diseases and let us hypothesize an important role of ACE and MTHFR system in the pathogenetic model of migraine for its capability to interfere with the endothelial regulation tone. Once an effective role in the genesis of migraine and in the increased risk of migrainous patients to evolve into an ischemic pathology has been obviously assigned to this genetic mutation, future researches must aim through wider and more controlled casistics also to clarify the role that drugs acting on these systems may have on the resolution of these diseases.
Collapse
Affiliation(s)
- V Pizza
- Neurophysiopathology Unit, S. Luca Hospital, Vallo della Lucania (Sa), Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Cozzolino D, Del Genio G, Santoriello C. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2010; 50:317-23. [DOI: 10.1093/rheumatology/keq176] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
29
|
Capasso I, Crispo A, Montella M, Esposito E, Cavalcanti E, D'Aiuto M, Capasso A, Vecchione A, Pedicini T, D'Aiuto G. P11 Metabolic syndrome as modifiable risk factor in breast cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70771-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
30
|
Abstract
4-(3,4-Dihydro-2,4-dioxo-2H-1,3-benzoxazin-3-yl)-butyric acid (7) and its ethyl (6), two potential y-aminobutyric acid (GABA) prodrugs, were synthesized and studied to determine their stability in aqueous buffer and their susceptibility to undergo enzymatic hydrolysis in vitro (mouse plasma). Both compounds were fairly stable in aqueous media, (t((1/2)) = 68.2 h and 25.7 h, respectively). The 3,4-dihydro-2,4-dioxo-2 H-I,3-benzoxazine ring underwent enzymatic hydrolysis (t((1/2)) =5.8 h) in compound 7, whereas in compound 6 it seemed not to be opened by mouse plasma esterases within the observation lime (3 h). Both compounds were tested for their central nervous system activity by using both anticonvulsive and behavioral tests. The anticonvulsive study was performed using the convulsive agent pentetrazole (PTX) and bicuculline. The anticonvulsive study indicated that compound both compounds 6 and 7 (10, 20 and 40 mg/kg, i.p.), injected 60 min before PTX (75 mg/kg, i.p.) or bicuculline (10 microg/intracerebroventricular (i.c.v.)/mouse) induced a dose-dependent and significant reduction of the convulsive activity of PTZ and bicuculline whereas it was ineffective if injected immediately before the convulsive agent. Both compounds 6 and 7 (10, 20 and 40 mg/kg, i.p.) did not significantly modify animal behavior or the nociceptive threshold of the animals. However, in PTZ- and bicuculline- treated mice, compound 7 showed significant activity, compared to compound 6, because it was active at relatively low doses. The behavior elements considered were locomotor activity, motor coordination, catalepsy, behavior and antinociception. The results of the behavoral study indicate that these new GABA mimetic drugs did not modify the animal behavior. Our data indicate that these new GABA mimetic drug possesses good anticonvulsive activity without altering the animalbehavior and their ability to block bicuculline-induced convulsions suggests that they could be a GABA(A) mimetic drug. Furthermore, since these compounds are able to act after systemic administration, our data suggest that these new GABA mimetic drug cross the blood-brain barrier.
Collapse
Affiliation(s)
- A Capasso
- Dipartimento di Scienze Farmaceutiche, Università di Salerno, Via Ponte Don Melillo, (84084) Fisciano, Salerno, Italia.
| | | |
Collapse
|
31
|
Loizzo S, Capasso A, Giuliani G, Loizzo A. Postnatal Repeated Mild Stress and DEγE Treatment Induce a Reduction of S of DBA/2J in Mice. LETT DRUG DES DISCOV 2009. [DOI: 10.2174/157018009787847837] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
32
|
Abstract
Recently, we have demonstrated that substitution of 1,2,3,4 tetrahyidroisoquinoline-3- carboxylic acid (Tic) in place of Gly2 in dynorphin A-(1-13)-NH2 (DYN) analogue (A) decreased the affinity to the kappa, delta, and micro receptors, and kappa selectivity. The doubly substituted analogue [2',6'-dimethyl-L-tyrosine (Dmt1)-Tic2]DYN (B) exhibited high delta-affinity (Ki=0.39 nM) while micro- and kappa-affinities were only an order of magnitude less (4-5 nM). Bioactivity of [Tic2]DYN peptide (A) on guinea-pig ileum and rabbit jejunum revealed potent delta- and kappa-antagonism thus indicating that the conversion from a kappa-agonist to antagonist occurred with the inclusion of Tic into DYN analogues, similar to the appearance of antagonist properties with delta-opioid agonists containing a Tic2 residue. The present study was undertaken to compare the k- and delta-opioid antagonistic activity of two [Tic2] DYN peptides (A and B) with naloxone a well known non selective opioid receptor antagonist. This comparison was performed by using the model of opioid withdrawal in vitro. Following a 4 min in vitro exposure to U50-488 H (10(-8) M), a selective k opioid receptor agonist, the guinea-pig isolated ileum exhibited a strong contracture after the addition of naloxone (10(-5) M). Also, following a 4 min in vitro exposure to deltorphin II (10(-8) M), a selective delta opioid receptor agonist, the rabbit jejunum exhibited a strong contracture after the addition of naloxone (10(-5) M). Results are expressed as percent of Ach contractions. In our study, we showed that in guinea pig ileum the peptide A (k opioid receptor antagonist) was able to induce a strong contracture at a concentration of 10(-9) M when injected 4 min after U50-488H (10(-8) M). Also, in rabbit jejunum the peptide B (delta-opioid receptor antagonist) was able to induce a strong contracture at a concentration of 10(-10) M when injected 4 min after deltorphin II (10(-8) M). The results of our experiments indicate that both peptide A (k receptor opiod antagonist) and peptide B (alpha receptor opioid antagonist) showed an antagonistic activity higher than naloxone.
Collapse
Affiliation(s)
- A Capasso
- Department of Pharmaceutical Sciences, University of Salerno, via Ponte Don Melillo (84084) Fisciano (Salerno), Italy.
| |
Collapse
|
33
|
Capasso A, De Feo V, De Simone F, Sorrentino L. Activity-directed Isolation of Spasmolytic (anti-cholinergic) Alkaloids from Brugmansia arborea (L.) Lagerheim. ACTA ACUST UNITED AC 2008. [DOI: 10.1076/phbi.35.1.43.13262] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- A Capasso
- Facolta di Farmacia, Universita degli Studi di Salerno, Piazza Vittorio Emanuele, 9,I-84084 Penta (Salerno) Italy
| | - V De Feo
- Facolta di Farmacia, Universita degli Studi di Salerno, Piazza Vittorio Emanuele, 9,I-84084 Penta (Salerno) Italy
| | - F De Simone
- Dipartimento di Farmacologia Sperimentale, Universita degli Studi Federico II,via D. Montesano, 49, I-80131 Napoli, Italy
| | - L Sorrentino
- Facolta di Farmacia, Universita degli Studi di Salerno, Piazza Vittorio Emanuele, 9,I-84084 Penta (Salerno) Italy
| |
Collapse
|
34
|
Affiliation(s)
- V De Feo
- School of Pharmacy, University of Salerno, Piazza Vittorio Emanuele 9, 84084,
Penta di Fisciano, Salerno
| | - A Capasso
- School of Pharmacy, University of Salerno, Piazza Vittorio Emanuele 9, 84084,
Penta di Fisciano, Salerno
- Department of Experimental Pharmacology University of Naples Federico II, via Domenico Montesano 49, 80131, Italy
| | - F De Simone
- School of Pharmacy, University of Salerno, Piazza Vittorio Emanuele 9, 84084,
Penta di Fisciano, Salerno
| | - L Sorrentino
- School of Pharmacy, University of Salerno, Piazza Vittorio Emanuele 9, 84084,
Penta di Fisciano, Salerno
| |
Collapse
|
35
|
Capasso A, Urrunaga R, Garofalo L, Sorrentino L, Aquino R. Phytochemical and pharmacological studies on medicinal herb Acicarpha tribuloides. ACTA ACUST UNITED AC 2008. [DOI: 10.1076/phbi.34.4.255.13230] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- A Capasso
- 1Centro Interdipartimentale di Chimica, Biologia e Tecnologia Farmaceutiche, Facolta di Farmacia, Universita di Salerno, Piazza Vittorio Emanuele 9, 84084, Penta di Fisciano, Italy
| | - R Urrunaga
- Dipartimento di Farmacologia Sperimentale, Universita di Napoli Federico II via Domenico Montesano 49, 80131, Napoli, Italy
| | - L Garofalo
- 1Centro Interdipartimentale di Chimica, Biologia e Tecnologia Farmaceutiche, Facolta di Farmacia, Universita di Salerno, Piazza Vittorio Emanuele 9, 84084, Penta di Fisciano, Italy
| | - L Sorrentino
- CEPLAM Universidad Nacional de San Antonio Abad de Cuzco, Avenida de Cultura, Cuzco, Peru
| | - R Aquino
- Dipartimento di Chimica delle Sostanze Naturali
| |
Collapse
|
36
|
Capasso A. Modulation by Dopaminergic System of Morphine Withdrawal: In Vitro Evidences. LETT DRUG DES DISCOV 2008. [DOI: 10.2174/157018008784619906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
37
|
Milano W, Grillo F, Del Mastro A, De Rosa M, Sanseverino B, Petrella C, Capasso A. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther 2007; 24:123-34. [PMID: 17526469 DOI: 10.1007/bf02850000] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Weight gain induced by antipsychotics is the second most frequently given reason for noncompliance with pharmacologic therapy; excessive sedative effects rank first, with extrapyramidal side effects ranking third. Frequently, weight gain leads to inconsistent pharmacologic treatment; this exposes patients to the risk of recurrent symptoms. In fact, one of the key contributors to good clinical outcomes in schizophrenic patients is compliance with pharmacologic treatment. The goals of this study were to evaluate weight gain in a group of patients treated with olanzapine, diet modifications, and moderate physical activity and to compare the findings with those from a second group of patients who were given only olanzapine treatment. For 8 wk, investigators followed 2 groups of patients suffering from schizophrenia and hypomania in bipolar disorder, according to the nosographic criteria of The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The first group (A) of 18 patients (9 female, 9 male) affected by manic episodes in bipolar disorder received olanzapine (10-20 mg/d), jogged lightly for 30 min 3 times a week, and complied with a diet that consisted of 500 kcal/d less than usual. The second group (B) of 10 patients (4 female, 6 male) with schizophrenia received only olanzapine (10-20 mg/d). All patients from both groups were weighed at the beginning of the observation period and weekly thereafter for 2 mo. After 2 mo of observation, group A showed a mean weight gain of 1.47 kg, whereas group B exhibited a mean weight gain of 3.5 kg; the difference between the 2 groups was almost 2 kg (P<.005). Group A showed a statistically significant reduction in weight gain compared with group B, clearly demonstrating the effectiveness of moderate physical activity and diet therapy in reducing weight gain in atypical antipsychotic treatment. Therefore, patient weight and body mass index must be monitored during the first weeks of antipsychotic treatment, with the goals of avoiding significant weight gain and treatment interruption.
Collapse
Affiliation(s)
- W Milano
- Mental Health Unit, District 44-ASL, Naples, Italy
| | | | | | | | | | | | | |
Collapse
|
38
|
De Blasio E, Racca A, Pellegrini C, Di Maria C, Giunta L, Lallo C, Bizzarro E, Prizio G, Capasso A. Impact of a selective digestive decontamination and nasal mupirocin on the incidence of ventilatory-associated pneumonia and the emergence of bacterial resistance. Crit Care 2007. [PMCID: PMC4095130 DOI: 10.1186/cc5236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
39
|
Ionata E, Canganella F, Bianconi G, Benno Y, Sakamoto M, Capasso A, Rossi M, La Cara F. A novel keratinase from Clostridium sporogenes bv. pennavorans bv. nov., a thermotolerant organism isolated from solfataric muds. Microbiol Res 2006; 163:105-12. [PMID: 17085026 DOI: 10.1016/j.micres.2006.08.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 08/03/2006] [Accepted: 08/03/2006] [Indexed: 11/19/2022]
Abstract
A bacterium which can grow on chicken feathers and which exhibits keratinolytic activity was isolated from solfataric muds. It was classified as belonging to the genus Clostridium and closely related to C. sporogenes. Based on its unique capability to degrade chicken feathers, it was designated as Clostridium sporogenes bv. pennavorans bv. nov. The keratinase purified from the culture supernatant is a monomer of 28.7kDa molecular mass. The enzyme is relatively thermostable and is active over a broad range of temperature and pH. Specific enzymatic assays demonstrate that keratinase can act on a large variety of soluble and insoluble protein substrates.
Collapse
Affiliation(s)
- E Ionata
- Institute of Protein Biochemistry--CNR, Naples, Italy
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
BACKGROUND Recently, potential liver toxicity was discussed with the intake of kava extract preparations (Piper methysticum) as anxiolytic drugs. The aim of this study was to test chronic toxicity in rats by oral application of an ethanolic kava full extract. METHODS Wistar rats of both sexes were fed 7.3 or 73 mg/kg body weight of ethanolic kava extract for 3 and 6 months. The animals were examined for changes in body weight, hematological and liver parameters, and macroscopical and microscopical histological changes in the major organs. RESULTS No signs of toxicity could be found. CONCLUSIONS The results are in accordance with the medical experience regarding the use of kava preparations and the long tradition of kava drinking in the South Pacific island states. Specifically, the results do not back the suspicion of potential liver toxicity.
Collapse
Affiliation(s)
- L Sorrentino
- Department of Experimental Pharmacology, University Frederico II, Via D Montesano 49, I-80131 Napoli, Italy.
| | | | | |
Collapse
|
41
|
Abstract
Our interest has been centered on isoquinoline alkaloids obtained from Argemone mexicana (Papaveraceae), Aristolochia constricta (Aristolochiaceae) and the opium alkaloid, papaverine. In this respect, the effect of these isoquinoline alkaloids was investigated on contractions induced by naloxone of isolated guinea pig ileum acutely exposed to morphine in vitro. The activity of these alkaloids was compared to the control compound, papaverine. Furthermore, the effect of these isoquinoline alkaloids was also determined on naloxone-precipitated withdrawal in isolated guinea pig ileum exposed to DAMGO (highly selective mu opioid receptor agonist) and U50-488H (highly selective kappa opioid receptor agonist) to test whether the possible interaction of isoquinoline alkaloids on opioid withdrawal involves mu- and/or kappa-opioid receptors. Isoquinoline alkaloids from A. mexicana (from 5 x 10(-6) to 1 x 10(-4) M), from A. constricta (1 x 10(-5) x 10(-5)-1 x 10(-4) M) as well as papaverine treatment (1 x 10(-7)-5 x 10(-6)-1 x 10(-6) M) before or after the opioid agonists were able of both preventing and reversing the naloxone-induced contraction after exposure to mu (morphine and DAMGO) or kappa (U50-488H) opiate receptor agonists in a concentration-dependent manner. Both acetylcholine response and electrical stimulation were also reduced by isoquinoline alkaloids and papaverine treatment as well as the final opiate withdrawal was still reduced. The results of the present study indicate that isoquinoline alkaloids as well as papaverine were able to produce significant influence on the opiate withdrawal in vitro and these compounds were able to exert their effects both at mu and kappa opioid agonists.
Collapse
Affiliation(s)
- A Capasso
- Dipartimento di Scienze Farmaceutiche, Università di Salerno, Via Ponte Don Melillo, 84084, Italy.
| | | | | | | | | |
Collapse
|
42
|
Capasso A, Azan G, Orlando L, Pellegrini C, Prizio G, Di Maria C, De Blasio E. Crit Care 2006; 10:P49. [DOI: 10.1186/cc4396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Azan G, Capasso A, Orlando L, Pellegrini C, Prizio G, Di Maria C, De Blasio E. Crit Care 2006; 10:P314. [DOI: 10.1186/cc4661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Abstract
Bulimia nervosa (BN) is one of the most common eating disorders in industrialized societies. It has been suggested that reduced serotonin activity triggers some of the cognitive and mood disturbances associated with BN. For this reason, the pharmacologic treatment of BN consists mainly of selective serotonin reuptake inhibitors (SSRIs), which have been proven effective. At present, the physiologic bases of this disorder are not yet completely understood. We conducted a randomized controlled trial to verify the efficacy of the SSRI fluvoxamine in patients with a diagnosis of BN. Twelve female outpatients aged 21 to 34 years with a diagnosis of BN-binge purging (as defined by the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders [DSM IV]) were randomly assigned to 2 treatment groups: the fluvoxamine 200 mg/day group and the placebo group. The patients underwent weekly clinical assessments for 12 weeks. At the end of the observation period, there was a statistically significant reduction in the number of binge-eating crises and purging episodes in the fluvoxamine group compared with placebo. In no case was treatment interrupted because of emergent side effects. These findings support the hypothesis that fluvoxamine is well tolerated and effective in reducing binge-eating crises and purging episodes in patients with BN.
Collapse
Affiliation(s)
- W Milano
- Department of Pharmaceutical Sciences, Mental Health Unit, University of Salerno, Naples, Italy
| | | | | | | |
Collapse
|
45
|
Abstract
Kava kava extract, Passiflora extract and a combination of both extracts, administered to mice, caused a significant decrease of the amphetamine-induced hypermotility and significant prolongation of sleeping phase induced by subcutaneous injection of barbiturates. Due to a synergism of both extracts, simultaneously administered the pharmacologically registered effect in both in vivo experiments was found to be superior over the sum of the single separately administered extracts.
Collapse
Affiliation(s)
- A Capasso
- 1st Department of Pharmaceutical Sciences, University of Salerno, Italy
| | | |
Collapse
|
46
|
Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005; 22:25-31. [PMID: 15943219 DOI: 10.1007/bf02850181] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Binge-eating disorder, which is characterized by repeated episodes of uncontrolled eating, is common in obese patients and is often accompanied by comorbid psychiatric disorders, especially depression. In previous studies, selective serotonin reuptake inhibitors have demonstrated efficacy in reducing the frequency of binge eating and addressing comorbid psychiatric disorders, but they have not shown the ability to promote weight loss. Sibutramine, a new serotonin and norepinephrine reuptake inhibitor, has been shown in short- and long-term studies to be effective in promoting and maintaining weight loss in obese patients who have binge-eating disorder. In this randomized, double-blind, placebo-controlled study, the efficacy, safety, and tolerability of sibutramine were evaluated in the treatment of binge-eating disorder in obese patients. Twenty patients were randomly assigned in equal numbers to receive either sibutramine 10 mg/day or placebo for 12 weeks. Assessments were made at baseline and every 2 weeks throughout the study. Binge frequency, defined as the number of days during the previous week that included binge-eating episodes, was the primary outcome measure. By the end of the study, the binge frequency among patients given sibutramine was significantly lower than that among those given placebo. The main adverse events in the sibutramine group were dry mouth and constipation. The findings suggest sibutramine is an effective medication in the treatment of binge-eating disorders and is well tolerated. In addition, it addresses the 3 main goals in the treatment of binge-eating disorder: reducing the frequency of binge eating, promoting and maintaining weight loss, and treating the comorbid psychiatric conditions.
Collapse
Affiliation(s)
- W Milano
- Mental Health Operations Unit, District 44 ASL, Napoli 1, Italy
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
Bulimia nervosa (BN) is one of the most frequently encountered eating disorders in industrialized societies. It has been suggested that reduced serotonin activity may trigger some of the cognitive and mood disturbances associated with BN. Thus, pharmacologic treatment of BN is mainly based on the use of selective serotonin reuptake inhibitors, which have proved effective. At present, the biological basis of this disorder is not completely clear. The aim of this randomized, controlled trial was to verify the efficacy of sertraline, a selective serotonin reuptake inhibitor, in a group of patients with a diagnosis of BN. Twenty female outpatients, with an age range of 24 to 36 years and a diagnosis of purging type BN as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), were assigned randomly to two treatment groups. The first group received sertraline 100 mg/day for 12 weeks; the second group received placebo. The study was conducted for 12 weeks, with weekly clinical assessments. At the end of the observation period, the group treated with sertraline had a statistically significant reduction in the number of binge eating crises and purging compared with the group who received placebo. In no case was treatment interrupted because of side effects. This study confirms that sertraline is well tolerated and effective in reducing binge-eating crises and purging in patients with BN.
Collapse
Affiliation(s)
- W Milano
- Mental Health Operations Unit, District 44 ASLNAI Naples, Italy
| | | | | | | |
Collapse
|
48
|
La Cara F, Alves L, Gírio F, Di Salle A, Capasso A, Rossi M. A New Dehydrogenase Specific Towards Aromatic Aldehydes From A Halophilic Bacterium. Protein Pept Lett 2003; 10:449-57. [PMID: 14561133 DOI: 10.2174/0929866033478645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A new enzyme showing a dehydrogenase activity towards aromatic aldehydes was isolated, purified and characterized from a halophilic strain isolated from saline environment. The enzyme is a monomer of 54 kDa; it is rather thermostable (optimal temperature: 50 degrees C) showing a broad spectrum of activity in a large pH range with the maximum at pH 9.5. The substrate specificity and the effect of ions were evaluated and compared with analogous described proteins.
Collapse
Affiliation(s)
- F La Cara
- Institute of Protein Biochemistry-C.N.R., Via P. Castellino, 111, 80131, Naples, Italy
| | | | | | | | | | | |
Collapse
|
49
|
Catara G, Ruggiero G, La Cara F, Digilio FA, Capasso A, Rossi M. A novel extracellular subtilisin-like protease from the hyperthermophile Aeropyrum pernix K1: biochemical properties, cloning, and expression. Extremophiles 2003; 7:391-9. [PMID: 12908102 DOI: 10.1007/s00792-003-0337-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2002] [Accepted: 05/06/2003] [Indexed: 10/26/2022]
Abstract
A novel extracellular serine protease designated Pernisine was purified to homogeneity and characterized from the archaeon Aeropyrum pernix K1. The molecular mass, estimated by SDS-PAGE analysis and by gel filtration chromatography, was about 34 kDa suggesting that the enzyme is monomeric. Pernisine was active in a broad range of pH (5.0-12.0) and temperature (60-120 degrees C) with maximal activity at 90 degrees C and between pH 8.0 and 9.0. In the presence of 1 mM CaCl(2) the activity, as a function of the temperature, reached a maximum at 90 degrees C but at 120 degrees C the enzyme retained almost 80% of its maximal activity. Activity inhibition studies suggest that the enzyme is a serine metalloprotease and biochemical data indicate that Pernisine is a subtilisin-like enzyme. The protease gene, identified from the sequenced genome of A. pernix, was amplified from total genomic DNA by PCR technique to construct the expression plasmid pGEX-Pernisine. The Pernisine, lacking the leader sequence, was expressed in Escherichia coli BL21 strain as a fusion protein with glutathione- S-transferase. The biochemical properties of the recombinant enzyme were found to be similar to those of the native enzyme.
Collapse
Affiliation(s)
- G Catara
- Institute of Protein Biochemistry, CNR, Via Marconi 10, 80125 Naples, Italy
| | | | | | | | | | | |
Collapse
|
50
|
Abstract
This study investigated the possible role of nitric oxide (NO) in the development of neocortical spike-and-wave spindling episodes (S&W) of DBA/2J mice. The administration of distilled water did not modify either the number or duration of S&W in DBA/2J mice during the whole recording period (240 min). L-N(G)-nitro arginine methyl ester (L-NAME) (3-300 microg/mouse, i.c.v.) dose-dependently reduced the S&W of DBA/2J mice. This effect appeared 30 min after drug administration and lasted for the duration of the recording period (240 min). In addition, L-NAME treatment did not induce significant alterations of stereotyped behaviour such as licking, sniffing, chewing or tremors of the head and body and behavioural excitability, whereas the electroencephalogram desynchronized pattern was also significantly reduced. By contrast D-N(G)-nitro arginine methyl ester at the same doses did not affect S&W of mice. The inhibitory effect of L-NAME on S&W of mice was dose-dependently reversed by L-arginine (L-ARG, 3-300 microg/mouse, i.c.v.) but not by D-arginine. Finally, glyceryl trinitrate on its own (3-300 microg/mouse, i.c.v.) significantly increased the S&W of mice and it was also able to reverse the inhibition on S&W of mice operated by L-NAME. These results provide evidence that NO may play a significant role in the development of brain excitability.
Collapse
Affiliation(s)
- A Capasso
- Dipartimento di Scienze Farmaceutiche, Università di Salerno, Via Ponte Don Melillo, (84084) Fisciano, Salerno, Italia.
| | | | | |
Collapse
|